^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YL201

    i
    Other names: YL201
    Associations

    News

    Trials
    Company:
    MediLink
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4d
    A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=162, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1 trial • Combination therapy • Metastases
    |
    Hansizhuang (serplulimab) • YL201
    2ms
    A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC (clinicaltrials.gov)
    P2, N=100, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    abiraterone acetate • YL201
    3ms
    A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P2 trial • Metastases
    |
    abiraterone acetate • YL201
    5ms
    A Study YL201 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=640, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    Trial completion date • Trial primary completion date • Metastases
    |
    YL201
    1year
    Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors (AACR 2023)
    Safety evaluations demonstrated acceptable safety profile and no off-target toxicity in monkeys. These non-clinical data suggest the stability of linker in circulation but efficiently release the payload in tumors, and eventually, expanded the therapeutic window.Taken together, preclinical data suggest that YL201 could be a promising treatment strategy for B7-H3 positive cancer patients.
    Preclinical • PARP Biomarker
    |
    CD28 (CD28 Molecule) • CASP7 (Caspase 7)
    |
    PARP1 elevation
    |
    YL201
    1year
    Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors (AACR 2023)
    GLP toxicity studies using cynomolgus monkeys showed that YL202 is well tolerated with calculated therapeutic index (TI, HNSTD/MED) of ~100 for repeat dosing. No lung or platelet toxicity findings were observed at doses up to the maximum tolerated dose (MTD).Based on these preclinical results, it demonstrates that YL202’s advanced ADC design results in an increased therapeutic margin, and YL201 could be further developed in HER3 positive cancer patients.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 elevation
    |
    BNT326 • YL201